MedTrace Logo

The Effects of SGLTi on Diabetic Cardiomyopathy

NCT04200586 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-08-03

No results posted yet for this study

Summary

Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is considered as a cardiac muscle disorder secondary to diabetes mellitus (DM). Certain studies show the clinical benefit of SGLT-s inhibitors on reducing cardiovascular outcomes amongst patients with type II DM that go beyond the correction of hyperglycemic perse. Thus an observational imaging study is proposed to identify mechanistic insights of the drug group over cardiovascular events.

Conditions

  • Type2 Diabetes
  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Dapagliflozin

Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • David Chung-Wah SIU, Prof · The University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2021-03-04
Completion
2021-09-30
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04200586 on ClinicalTrials.gov